Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) and LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.
Risk and Volatility
Lyra Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Institutional and Insider Ownership
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent recommendations for Lyra Therapeutics and LENZ Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| LENZ Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
LENZ Therapeutics has a consensus target price of $23.00, suggesting a potential upside of 625.32%. Given LENZ Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Lyra Therapeutics.
Profitability
This table compares Lyra Therapeutics and LENZ Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lyra Therapeutics | N/A | N/A | N/A |
| LENZ Therapeutics | -586.74% | -53.39% | -49.14% |
Earnings and Valuation
This table compares Lyra Therapeutics and LENZ Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lyra Therapeutics | $600,000.00 | 0.56 | -$28.92 million | ($19.15) | -0.01 |
| LENZ Therapeutics | $21.48 million | 4.64 | -$82.13 million | ($4.09) | -0.78 |
Lyra Therapeutics has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
LENZ Therapeutics beats Lyra Therapeutics on 8 of the 14 factors compared between the two stocks.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
